HomeCompareOPTZF vs PFE

OPTZF vs PFE: Dividend Comparison 2026

OPTZF yields 42.33% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OPTZF wins by $213.5K in total portfolio value
10 years
OPTZF
OPTZF
● Live price
42.33%
Share price
$4.72
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$263.1K
Annual income
$46,592.70
Full OPTZF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — OPTZF vs PFE

📍 OPTZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPTZFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPTZF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OPTZF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPTZF
Annual income on $10K today (after 15% tax)
$3,598.40/yr
After 10yr DRIP, annual income (after tax)
$39,603.80/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, OPTZF beats the other by $17,283.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPTZF + PFE for your $10,000?

OPTZF: 50%PFE: 50%
100% PFE50/50100% OPTZF
Portfolio after 10yr
$156.3K
Annual income
$36,425.71/yr
Blended yield
23.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

OPTZF
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPTZF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPTZFPFE
Forward yield42.33%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$263.1K$49.6K
Annual income after 10y$46,592.70$26,258.71
Total dividends collected$201.2K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OPTZF vs PFE ($10,000, DRIP)

YearOPTZF PortfolioOPTZF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$14,933$4,233.41$9,153$693.39+$5.8KOPTZF
2$21,887$5,908.35$8,593$849.25+$13.3KOPTZF
3$31,512$8,093.04$8,336$1,066.78+$23.2KOPTZF
4$44,608$10,889.77$8,437$1,384.80+$36.2KOPTZF
5$62,137$14,406.78$9,013$1,875.40+$53.1KOPTZF
6$85,242$18,755.28$10,306$2,680.72+$74.9KOPTZF
7$115,255$24,045.96$12,820$4,101.38+$102.4KOPTZF
8$153,708$30,385.34$17,673$6,826.70+$136.0KOPTZF
9$202,340$37,871.94$27,543$12,591.86+$174.8KOPTZF
10$263,096$46,592.70$49,560$26,258.71+$213.5KOPTZF

OPTZF vs PFE: Complete Analysis 2026

OPTZFStock

OptiCept Technologies AB (publ) develops a technology that controls and applies electrical pulses to optimize various biological processes in Sweden and internationally. The company offers foodtech products, such as juiceCEPT, a c machine; juiceCEPT+, an application for the juice industry; oliveCEPT that deploys a pre-treatment to olive paste in extra virgin olive oil production (EVOO) for better quality of the product and increases extracted EVOO yield; wineCEPT, a technology for the treatment of targets cell membranes in biomass; and dryCEPT to reduce drying time, enhanced flavor, and vivid color on the final dried products. It also provides planttech products, including OptiBoost for cut flowers and OptiBoost for cuttings. The company's products are used for applications in beer, dairy, flowers, food oils, juice, plant milk, and wine. The company was formerly known as OptiFreeze AB (publ) and changed its name to OptiCept Technologies AB (publ) in July 2021. OptiCept Technologies AB (publ) was incorporated in 2011 and is headquartered in Lund, Sweden.

Full OPTZF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this OPTZF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPTZF vs SCHDOPTZF vs JEPIOPTZF vs OOPTZF vs KOOPTZF vs MAINOPTZF vs JNJOPTZF vs MRKOPTZF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.